These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

280 related items for PubMed ID: 12869391

  • 1. The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolase.
    MacInnes A, Fairman DA, Binding P, Rhodes Ja, Wyatt MJ, Phelan A, Haddock PS, Karran EH.
    Circ Res; 2003 Aug 08; 93(3):e26-32. PubMed ID: 12869391
    [Abstract] [Full Text] [Related]

  • 2. Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme a thiolase.
    Lopaschuk GD, Barr R, Thomas PD, Dyck JR.
    Circ Res; 2003 Aug 08; 93(3):e33-7. PubMed ID: 12869392
    [Abstract] [Full Text] [Related]

  • 3. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase.
    Kantor PF, Lucien A, Kozak R, Lopaschuk GD.
    Circ Res; 2000 Mar 17; 86(5):580-8. PubMed ID: 10720420
    [Abstract] [Full Text] [Related]

  • 4. The effects of chronic trimetazidine treatment on mechanical function and fatty acid oxidation in diabetic rat hearts.
    Onay-Besikci A, Guner S, Arioglu E, Ozakca I, Ozcelikay AT, Altan VM.
    Can J Physiol Pharmacol; 2007 May 17; 85(5):527-35. PubMed ID: 17632588
    [Abstract] [Full Text] [Related]

  • 5. A comparison between ranolazine and CVT-4325, a novel inhibitor of fatty acid oxidation, on cardiac metabolism and left ventricular function in rat isolated perfused heart during ischemia and reperfusion.
    Wang P, Fraser H, Lloyd SG, McVeigh JJ, Belardinelli L, Chatham JC.
    J Pharmacol Exp Ther; 2007 Apr 17; 321(1):213-20. PubMed ID: 17202401
    [Abstract] [Full Text] [Related]

  • 6. Early administration of trimetazidine may prevent or ameliorate diabetic cardiomyopathy.
    Wenmeng W, Qizhu T.
    Med Hypotheses; 2011 Feb 17; 76(2):181-3. PubMed ID: 20932648
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Optimizing cardiac energy metabolism: how can fatty acid and carbohydrate metabolism be manipulated?
    Lopaschuk GD.
    Coron Artery Dis; 2001 Feb 17; 12 Suppl 1():S8-11. PubMed ID: 11286307
    [Abstract] [Full Text] [Related]

  • 11. Cardioprotective effects of trimetazidine: a review.
    Marzilli M.
    Curr Med Res Opin; 2003 Feb 17; 19(7):661-72. PubMed ID: 14606990
    [Abstract] [Full Text] [Related]

  • 12. Trimetazidine therapy prevents obesity-induced cardiomyopathy in mice.
    Ussher JR, Fillmore N, Keung W, Mori J, Beker DL, Wagg CS, Jaswal JS, Lopaschuk GD.
    Can J Cardiol; 2014 Aug 17; 30(8):940-4. PubMed ID: 25064584
    [Abstract] [Full Text] [Related]

  • 13. Malonyl coenzyme a decarboxylase inhibition protects the ischemic heart by inhibiting fatty acid oxidation and stimulating glucose oxidation.
    Dyck JR, Cheng JF, Stanley WC, Barr R, Chandler MP, Brown S, Wallace D, Arrhenius T, Harmon C, Yang G, Nadzan AM, Lopaschuk GD.
    Circ Res; 2004 May 14; 94(9):e78-84. PubMed ID: 15105298
    [Abstract] [Full Text] [Related]

  • 14. [Medicines interacting with mitochondria: anti-ischemic effects of trimetazidine].
    Spedding M, Tillement JP, Morin D, Le Ridant A.
    Therapie; 1999 May 14; 54(5):627-35. PubMed ID: 10667101
    [Abstract] [Full Text] [Related]

  • 15. [Ischemic heart disease and left ventricular dysfunction: the role of trimetazidine].
    Belardinelli R.
    Ital Heart J; 2004 Mar 14; 5 Suppl 2():23S-28S. PubMed ID: 15074774
    [Abstract] [Full Text] [Related]

  • 16. Modulation of fatty acids oxidation in heart failure by selective pharmacological inhibition of 3-ketoacyl coenzyme-A thiolase.
    Fragasso G, Spoladore R, Cuko A, Palloshi A.
    Curr Clin Pharmacol; 2007 Sep 14; 2(3):190-6. PubMed ID: 18690865
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts--role of late sodium current and intracellular ion accumulation.
    Sossalla S, Wagner S, Rasenack EC, Ruff H, Weber SL, Schöndube FA, Tirilomis T, Tenderich G, Hasenfuss G, Belardinelli L, Maier LS.
    J Mol Cell Cardiol; 2008 Jul 14; 45(1):32-43. PubMed ID: 18439620
    [Abstract] [Full Text] [Related]

  • 20. Metabolic modulators for chronic cardiac ischemia.
    Parang P, Singh B, Arora R.
    J Cardiovasc Pharmacol Ther; 2005 Dec 14; 10(4):217-23. PubMed ID: 16382258
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.